A Polygenic Risk Score to Predict Future Adult Short Stature Among Children by Lu, Tianyuan et al.
                          Lu, T., Forgetta, V., Wu, H., Perry, J. R. B., Ong, K. K., Greenwood,
C. M. T., Timpson, N. J., Manoousaki, D., & Richards, J. B. (2021). A
Polygenic Risk Score to Predict Future Adult Short Stature Among
Children. Journal of Clinical Endocrinology and Metabolism, 106(7),
1918-1928. [dgab215]. https://doi.org/10.1210/clinem/dgab215
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1210/clinem/dgab215
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via
Endocrine Society at https://doi.org/10.1210/clinem/dgab215 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. XX, No. XX, 1–11
doi:10.1210/clinem/dgab215
Clinical Research Article
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
https://academic.oup.com/jcem   1
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Clinical Research Article
A Polygenic Risk Score to Predict Future Adult 
Short Stature Among Children
Tianyuan  Lu,1,2 Vincenzo  Forgetta,1 Haoyu  Wu,1,3 John  R.  B.  Perry,4 
Ken  K.  Ong,4,5 Celia  M.  T.  Greenwood,1,3,6,7 Nicholas  J.  Timpson,8 
Despoina Manousaki,1,9 and J. Brent Richards1,6,10
1Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Canada; 2Quantitative 
Life Sciences Program, McGill University, Montréal, Canada; 3Department of Epidemiology, Biostatistics 
and Occupational Health, McGill University, Montréal, Canada; 4Medical Research Council Epidemiology 
Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK; 5Department of Pediatrics, 
University of Cambridge School of Clinical Medicine, Cambridge, UK; 6Department of Human Genetics, 
McGill University, Montréal, Canada; 7Gerald Bronfman Department of Oncology, McGill University, 
Montréal, Canada; 8Medical Research Council Integrative Epidemiology Unit, Department of Population 
Health Sciences, University of Bristol, Bristol, United Kingdom; 9Department of Pediatrics, Université 
de Montréal, Montréal, Canada; and 10Department of Twin Research and Genetic Epidemiology, King’s 
College London, London, UK
ORCiD numbers: 0000-0002-5664-5698 (T. Lu); 0000-0002-6061-4720 (V. Forgetta); 0000-0002-3746-9086 (J. B. Richards).
Received: 2 February 2021; Editorial Decision: 29 March 2021; First Published Online: 31 March 2021; Corrected and Typeset: 
20 May 2021. 
Abstract 
Context: Adult height is highly heritable, yet no genetic predictor has demonstrated 
clinical utility compared to mid-parental height.
Objective: To develop a polygenic risk score for adult height and evaluate its clinical 
utility.
Design: A polygenic risk score was constructed based on meta-analysis of genomewide 
association studies and evaluated on the Avon Longitudinal Study of Parents and 
Children (ALSPAC) cohort.
Subjects: Participants included 442 599 genotyped White British individuals in the UK 
Biobank and 941 genotyped child-parent trios of European ancestry in the ALSPAC cohort.
Interventions: None.
Main Outcome Measures: Standing height was measured using stadiometer; Standing 
height 2 SDs below the sex-specific population average was considered as short stature.
Results: Combined with sex, a polygenic risk score captured 71.1% of the total variance in 
adult height in the UK Biobank. In the ALSPAC cohort, the polygenic risk score was able to 
identify children who developed adulthood short stature with an area under the receiver 








/dgab215/6206752 by guest on 11 June 2021
2  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. XX, No. XX
height. Combining this polygenic risk score with mid-parental height or only one of the 
child’s parent’s height could improve the AUROC to at most 0.90. The polygenic risk score 
could also substitute mid-parental height in age-specific Khamis-Roche height predictors 
and achieve an equally strong discriminative power in identifying children with a short 
stature in adulthood.
Conclusions: A polygenic risk score could be considered as an alternative or adjunct to 
mid-parental height to improve screening for children at risk of developing short stature 
in adulthood in European ancestry populations.
Key Words: polygenic risk score, adult height prediction, short stature, parental height, UK Biobank, ALSPAC
Predicting adult height is important to monitoring child-
hood growth and development, particularly for children in 
some jurisdictions who may be considered for growth hor-
mone therapy for “idiopathic short stature” (1-3). Various 
approaches have been developed and clinically adopted for 
adult height prediction, based on current height measures 
and bone age as measured by hand and wrist X-ray, such 
as the Bayley-Pinneau method (4), the Tanner-Whitehouse 
methods (5,6), and the Roche-Wainer-Thissen method (7). 
While bone age has been recognized as one of the most 
important predictors of final adult height (8) and has been 
employed in these prediction approaches, measuring bone 
age requires an X-ray and a radiologist’s interpretation of 
the images and calculation of the predicted adult height. 
Also, in some medical conditions affecting bone structure 
(such as glycogen storage diseases (9)), determination of 
bone age from X-ray can be challenging.
Since height is highly heritable, with an estimated her-
itability of approximately 80% (10,11), efforts have been 
made to genetically predict height. In the 19th century, 
the concept of mid-parental height was proposed (12). 
It has been either used directly as an empirical predictor 
of adult height or incorporated into other height predic-
tion methods, such as the bone age-free Khamis-Roche 
method (13), to represent the genetic contribution to an 
individual’s adult height. Nevertheless, mid-parental height 
has a few noteworthy limitations. First, it is a surrogate 
of genetic effects and does not reflect the exact number 
of height-influencing alleles inherited from the parents. 
Consequently, its accuracy as a predictor decreases when 
the precision of the measurement of parental heights de-
creases. This can occur when the parents’ height is esti-
mated or measured after it has started declining from peak 
adult height. Further, when one or both biological parents’ 
heights are unknown (which often happens for adopted 
children and nonnuclear families or when a parent is de-
ceased) calculating mid-parental height may be impossible. 
Hence, finding alternative and more accurate genetic pre-
dictors of adult height could be helpful to clinicians.
Directly assessing the presence of alleles that influence 
height has become practical and relatively low cost through 
the use of genomewide genotyping. With large genotyped 
cohorts, such as the UK Biobank (14), polygenic risk scores 
for complex traits of high heritability and polygenicity have 
been developed and achieved high predictive and discrim-
inative power (15-18). Although it has been shown that at 
least 3290 near-independent genomewide significant single 
nucleotide polymorphisms (SNPs) are associated with adult 
height (19), a recently constructed polygenic risk score has 
been able to explain about 40% of the total variance in sex-
adjusted height z-scores (20).
In this study, we sought to develop and optimize a 
polygenic risk score for adult height using state-of-the-art 
methods based on 607  346 individuals of European an-
cestry from the UK Biobank and the Genetic Investigation 
of Anthropometric Traits (GIANT) study (21). We then 
evaluated how well such a polygenic risk score performed 
compared to mid-parental height in its ability to predict 
adult height of 941 children from the Avon Longitudinal 
Study of Parents and Children (ALSPAC) (22,23). Last, we 
tested the ability of the polygenic risk score to identify chil-
dren who would later have an adulthood short stature.
Methods
Study Cohorts
The UK Biobank study recruited more than 500 000 par-
ticipants who were enrolled between 2006 and 2010 and 
were aged between 40 and 69 years, at multiple recruit-
ment centers in the United Kingdom (14). Demographic 
and anthropometric measurements were collected upon 
recruitment (Table 1). Shoeless standing height was 
measured using a Seca 202 mechanical telescopic height 
measuring rod. Participants of the UK Biobank were geno-
typed using the Applied Biosystems™ UK BiLEVE Axiom™ 
Array or UK Biobank Axiom™ Array (14). The genotypes 
were imputed to the Haplotype Reference Consortium 
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minor allele frequency >0.01% and an imputation infor-
mation score >0.8 were retained. Ethics approval for the 
UK Biobank study was obtained from the North West 
Centre for Research Ethics Committee (11/NW/0382). The 
UK Biobank ethics statement is available at https://www.
ukbiobank.ac.uk/the-ethics-and-governance-council/. All 
UK Biobank participants provided informed consent at 
recruitment.
The ALSPAC cohort initially recruited 14 541 pregnant 
women who had an expected delivery date between April 
1991 and December 1992 in the Bristol and Avon areas in 
the United Kingdom. Details of this prospective cohort have 
been described previously (22,23). Children in the ALSPAC 
cohort were genotyped using the Illumina HumanHap550 
quad genotyping platforms and the genotypes were im-
puted to the 1 000 Genomes Phase 3 reference panel (25). 
A  total of 8932 samples were available for children of 
European ancestry. Shoeless adult standing height (at age 
24 (26)), or individuals who were originally the children 
in the cohort, as well as shoeless standing height of both 
biological parents (available for 1532 children) were meas-
ured during clinical visits using a Harpenden stadiometer 
(Holtain Ltd). Among 3078 genotyped children who had 
measured adult height, 941 had height measured for both 
biological parents (Table 1), a further 1305 only had meas-
ured maternal height, and 151 only had measured paternal 
height. Shoeless height and weight measures of children 
during puberty (between ages 8 and 17) was collected from 
a “Growing and Changing” questionnaire, which was dis-
tributed to participants recurrently between September 
1999 and February 2010 (27). These questionnaires were 
completed by either a parent or a child. The children were 
asked to stand barefoot straight against a wall to mark 
at the highest point on the head and to measure the dis-
tance from the mark on the floor. No specific instruction 
was provided for measuring weight. Please note that the 
study website contains details of all the data that are avail-
able through a fully searchable data dictionary and variable 
search tool (http://www.bristol.ac.uk/alspac/researchers/
out-data/).
Ethical approval for the study was obtained from the 
ALSPAC Ethics and Law Committee and the Local Research 
Ethics Committees. Consent for biological samples has 
been collected in accordance with the Human Tissue Act 
(2004). Informed consent for the use of data collected via 
questionnaires and clinics was obtained from participants 
following the recommendations of the ALSPAC Ethics and 
Law Committee at the time.
Development of a Polygenic Risk Score
Details of polygenic risk score construction and initial evalu-
ation are provided in supplementary notes in (28) and sum-
marized in Figure 1. Briefly, we first performed genomewide 
association study for height in the UK Biobank, based 
on 354  058 White British ancestry individuals. Next, we 
Table 1. Cohort characteristics
Female Male
UK Biobank training set (N = 354 058)   
 Sample size (%) 191 361 (54.0) 162 697 (46.0)
 Mean height in cm (SD) 162.6 (6.2) 175.8 (6.8)
 Mean age (SD) 56.7 (7.9) 57.1 (8.1)
UK Biobank model selection set (N = 6 639)   
 Sample size (%) 3635 (54.8) 3004 (45.2)
 Mean height in cm (SD) 162.8 (6.2) 175.7 (6.7)
 Mean age (SD) 56.5 (7.8) 57.1 (8.1)
UK Biobank test set (N = 81 902)   
 Sample size (%) 44 304 (54.1) 37 598 (45.9)
 Mean height in cm (SD) 162.6 (6.3) 175.9 (6.8)
 Mean age (SD) 56.6 (7.9) 57.1 (8.1)
ALSPACa   
 Children without mid-parental heightb (N = 2137)   
  Sample size (%) 1343 (62.8) 794 (37.2)
  Mean height in cm (SD) 165.9 (6.2) 180.1 (6.7)
 Children with mid-parental height (N = 941)   
  Sample size (%) 541 (57.5) 400 (42.5)
  Mean height in cm (SD) 166.5 (6.0) 180.1 (6.8)
All Individuals had a European ancestry.
aOnly 3078 genotyped children with measured adult height were included.
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meta-analyzed the UK Biobank-based genomewide associ-
ation study summary statistics with those provided by the 
GIANT study (21), which included 253 288 European an-
cestry individuals. We then leveraged a set of state-of-the-art 
approaches, including linkage disequilibrium-pruning and 
P-value thresholding (29), LDpred (16), and least absolute 
shrinkage and selection operator (30) regression, to de-
velop a series of new candidate polygenic risk scores based 
on a random training-model selection-test split in the UK 
Biobank (Table 1; supplementary notes in (28)). We found 
that a polygenic risk score generated by least absolute 
shrinkage and selection operator regression that included 
33 938 SNPs demonstrated the best predictive power in the 
UK Biobank model selection set; thus, we adopted this op-
timized polygenic risk score for all downstream assessments 
(supplementary notes in (28)).
Comparison of Polygenic Risk Score and 
Mid-Parental Height
We compared the predictive performance of the polygenic 
risk score and of the mid-parental height in predicting 
children’s adult height leveraging the ALSPAC cohort. Mid-
parental height was calculated as (31)
(Maternal height + Paternal height) /2 − 6.5 cm for girls
and
(Maternal height + Paternal height) /2
+ 6.5 cm for boys.
We also included comparison with an adapted form of mid-
parental height (32):
0.75× (Maternal height + Paternal height) /2
+ 37.85 cm for girls
and
0.78× (Maternal height + Paternal height) /2
+ 45.99 cm for boys.
This adapted mid-parental height predictor was derived 
from a Swedish population-based study including 2402 
children by fitting sex-specific linear regression models (32).
Polygenic risk scores were calculated for each of the 
3078 genotyped children with measured adult height. SNPs 
that were included in the UK Biobank-based score but were 
not present in the ALSPAC data were discarded.
We evaluated the predictive performance of these 2 
height predictors by proportion of variance explained and 
the root mean square error (RMSE). We defined those with 
relative short stature as being among the 2.3% shortest 
(corresponding to 2 SDs below the mean in the ALSPAC 
cohort) in females and males, separately. We performed 
logistic regression and compared predicted to measured 
height again using the area under the receiver operating 
characteristic curve (AUROC) and the area under the 
precision-recall curve (AUPRC). We also tested whether lin-
early combining the polygenic risk score with mid-parental 
height or with maternal or paternal height only could sig-
nificantly improve prediction accuracy by likelihood ratio 
test of linear regression models and by comparing binary 
prediction metrics. All assessments included sex-specific 
analyses.
Use of Polygenic Risk Score in Khamis-Roche 
Predictor
In addition, we calculated Khamis-Roche adult height pre-
dictors (13), which incorporate a child’s age, current height, 
current weight, and mid-parental height, for children with 
self-reported height and weight during puberty. We inves-
tigated whether the mid-parental height used in this pre-
dictor could be replaced by the genetically predicted height 
by the polygenic risk score and whether this substitution 
affected predictive performance.
Results
Polygenic Risk Score Achieved Comparable 
Predictive Performance as Mid-parental Height to 
Predict Final Adult Height
In the UK Biobank test set consisting of 81 902 individ-
uals (Table 1), in combination with age, sex, recruitment 
center, genotyping array, and the first 20 genetic prin-
cipal components (to account for population stratifica-
tion (14,15,18,33,34)), a polygenic risk score was able 
to capture 71.1% [95% confidence interval (CI): 70.8%-
71.4%] of the total variance in measured adult height (sup-
plementary notes and Supplementary Figure 1 in (28)). In 
the ALSPAC cohort, among 941 children for whom mid-
parental height prediction was available (Table 1), the poly-
genic risk score, together with sex, explained 71.0% (95% 
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CI: 67.9%-74.1%) of the total variance in adult height (Fig. 
2A). This value was similar to the 72.6% (69.6%-75.6%) 
variance explained by mid-parental height (Fig. 2B) and 
was consistent in 541 females [adjusted R2 = 38.5% (95% 
CI: 32.1%-44.9%) for the polygenic risk score vs 41.8% 
(95% CI: 35.5%-48.1%) for mid-parental height] and 400 
males [adjusted R2 = 37.9% (95% CI: 30.%5-45.4%) for 
the polygenic risk score vs 45.0% (95% CI: 37.8-52.1%) 
by mid-parental height]. Meanwhile, the polygenic risk 
score had an overall prediction RMSE of 4.96 cm, margin-
ally higher than that of the mid-parental height (4.82 cm; 
Supplementary Figure 2A in (28)).
When predicting adult short stature in a model 
including sex, the polygenic risk score achieved an AUROC 
of 0.843 (95% CI: 0.796-0.890) (Supplementary Figure 2B 
in (28)) and an AUPRC of 0.284 (95% CI: 0.102-0.500) 
(Supplementary Figure 2C in (28)) to identify children who 
would have adult short stature. The mid-parental height 
achieved an AUROC of 0.879 (95% CI: 0.840-0.919) 
(Supplementary Figure 2B in (28)) and an AUPRC of 0.326 
(95% CI: 0.127-0.546) (Supplementary Figure 2C in (28)). 
Specifically, each SD decrease in the polygenic risk score 
conferred a 1.62-fold (95% CI: 1.34-2.02) increased odds 
of having an adulthood short stature for females, with the 
AUROC being 0.861 (95% CI: 0.814-0.907) (Fig. 2C) and 
AUPRC being 0.373 (95% CI: 0.087-0.651) (Fig. 2D). The 
predictive performance was slightly lower for males, as 
the odds of having an adulthood short stature increased 
1.43-fold (95% CI: 1.20-1.75) per SD decrease in the 
polygenic risk score, with AUROC being 0.820 (95% CI: 
0.731-0.909) (Fig. 2E) and AUPRC being 0.181 (95% CI: 
0.044-0.518) (Fig. 2F). In contrast, each SD decrease in 
mid-parental height conferred a 1.53-fold (95% CI: 1.33-
1.81) and 1.34-fold (95% CI: 1.15-1.60) increased odds 
of having an adulthood short stature in females and males, 
respectively. Its discriminative power was higher than that 
of the polygenic risk score for females, with higher AUROC 
(0.943; 95% CI: 0.926-0.960) (Fig. 2C) and AUPRC (0.435; 
95% CI: 0.145-0.702) (Fig. 2D). In males, the mid-parental 
height had a lower AUROC (0.795; 95% CI: 0.709-0.882) 
(Fig. 2E) and a higher AUPRC than the polygenic risk score 
(0.237; 95% CI: 0.042-0.653) (Fig. 2F), but both over-
lapped with those of the polygenic risk score.
Possibly due to population specificity, compared to the 
ordinary mid-parental height, the adapted mid-parental 
height predictor (see previous discussion on methods) de-
rived from a Swedish population did not demonstrate su-
perior predictive power [adjusted R2 = 69.3% (95% CI: 
66.1%-72.6%)] (Supplementary Figure 3 in (28)), predic-
tion RMSE = 5.10 cm (Supplementary Figure 2A in (28)), 
or discriminative power in identifying children at risk 
for developing adulthood short stature [AUROC = 0.877 
(95% CI: 0.837-0.918); AUPRC = 0.291 (95% CI: 0.122-
0.539); combined with sex] (Supplementary Figure 2B and 
2C in (28)). We therefore did not include this adapted mid-
parental height predictor in further analyses.
A Polygenic Risk Score May Be Combined With 
Parental Height for Improved Prediction
Often in clinical settings, the height of only 1 parent is 
known. In the same ALSPAC test set of 941 children, to-
gether with sex, a joint predictor combining the polygenic 
risk score and maternal height achieved an adjusted R2 of 
75.5% (95% CI: 72.7%-78.2%) (Supplementary Figure 
4A in (28)) compared to 66.1% (95% CI: 62.6%-69.6%; 
likelihood ratio test P-value = 6.2 × 10−93) by the maternal 
height; a joint predictor combining the polygenic risk score 
and paternal height achieved an adjusted R2 of 75.2% (95% 
CI: 72.5%-78.0%) (Supplementary Figure 4B in (28)) com-
pared to 64.5% (95% CI: 60.9%-68.1%; likelihood ratio 
test P-value = 2.0 × 10-12) by the paternal height. When 
identifying children who would have an adulthood short 
stature, maternal height, together with sex, had an AUROC 
of 0.812 (95% CI: 0.776-0.848) and an AUPRC of 0.133 
(95% CI: 0.040-0.279); However, combining this with the 
polygenic risk score improved the AUROC to 0.896 (95% 
CI: 0.859-0.932) and the AUPRC to 0.322 (95% CI: 0.129-
0.524). Similarly, combining the paternal height with the 
polygenic risk score improved the AUROC from 0.825 
(95% CI: 0.772-0.878) to 0.882 (95% CI: 0.834-0.931) 
and the AUPRC from 0.255 (0.082-0.480) to 0.424 (95% 
CI: 0.208-0.624). These results were consistent in females 
and males (Supplementary Figure 4C-4F in (28)).
Furthermore, a joint predictor combining the polygenic 
risk score and the mid-parental height achieved an ad-
justed R2 of 78.5% (95% CI: 76.0%-80.9%), with 55.4% 
(95% CI: 49.9%-61.0%) in females and 55.9% (95% 
CI: 49.5%-62.3%) in males (Supplementary Figure 5 in 
(28)), as well as a substantially lower prediction RMSE of 
4.27 cm (Supplementary Figure 2A in (28)). This improve-
ment was significant over using the polygenic risk score 
(likelihood ratio test P-value = 6.3 × 10−73) or the mid-
parental height (likelihood ratio test P-value = 5.9 × 10−58) 
alone. The ability to identify individuals with an adult-
hood short stature was also improved with an AUROC of 
0.904 (95% CI: 0.862-0.947) (Supplementary Figure 2B 
in (28)) and an AUPRC of 0.490 (95% CI: 0.254-0.710) 
(Supplementary Figure 2C in (28)), in models including 
sex. Specifically, the AUROC increased to 0.969 (95% 
CI: 0.955-0.983) in females (Fig. 2C) and 0.821 (95% 
CI: 731-0.911) in males (Fig. 2E); the AUPRC increased 
to 0.530 (95% CI: 0.227-0.824) in females (Fig. 2D) and 
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Polygenic Risk Score Could Substitute Mid-
Parental Height in Khamis-Roche Approach for 
Improved Prediction
Khamis-Roche adult height predictors were derivable for 
varying sample sizes at 13 time points (Fig. 3). At ages 8, 
8.5, 9.5, and 10.5, we tested the performance of substi-
tuting mid-parental height with the polygenic risk score 
in the Khamis-Roche approach. We found that this led 
to marginally higher proportion of variance explained in 
adult height as well as slightly lower prediction RMSE 
(Fig. 3A and 3B). At ages ≥11 years, the 2 Khamis-Roche 
predictors displayed no distinguishable difference. These 
findings were consistent in females and males, respectively 
(Supplementary Figure 6 in (28)). Although underpowered 
by the limited number of short stature cases, the polygenic 
risk score-based Khamis-Roche predictor and the mid-
parental height-based Khamis-Roche predictor had highly 
consistent discriminative power in identifying children who 
would have a short stature in adulthood (Supplementary 
Figure 7 in (28)).
Figure 2. Comparison of predictive performance of the polygenic risk score and the mid-parental height in the ALSPAC cohort (N = 941). (A) The gen-
etically predicted height by the polygenic risk score and (B) the mid-parental height were almost equally correlated with the measured adult height of 
children. (C) Receiver operating characteristic curve and (D) precision recall curve comparing discriminative power for individuals with short stature 
of the polygenic risk score, the mid-parental height, and combining these 2 predictors in females. (E) Receiver operating characteristic curve and 
(F) precision recall curve comparing discriminative power for individuals with short stature of the polygenic risk score, the mid-parental height, and 
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Discussion
Accurate prediction of adult height is important for the 
management of short stature in childhood. As well as 
selecting which children may require growth hormone 
therapy for idiopathic short stature (1-3), it may also 
help to inform which children should be further investi-
gated for chronic health conditions affecting growth, such 
as growth hormone deficiency or genetic syndromes (35). 
Given the exceptionally high heritability of height, there 
have been long-standing interest and efforts to genetically 
predict adult height. Yet, the most commonly used genetic 
predictor has been the mid-parental height, which simply 
averages the height of a child’s biological parents and ad-
justs for the sex of the child. In this study, we constructed 
efficient polygenic risk scores for adult height, leveraging 
> 600  000 individuals of European ancestry. Using an 
Figure 3. The polygenic risk score may quantify genetic contribution in Khamis-Roche method in place of the mid-parental height. (A) Proportion of 
variance explained and (B) prediction root mean square error by Khamis-Roche predictors as well as the polygenic risk score and the mid-parental 
height are compared based on children with available pubertal development information in the ALSPAC cohort. (C) Sample sizes at ages 8 to 17. Time 
points at which both females and males had ≥50 samples were retained. Children’s chronological age at each survey was rounded to the nearest 0.5 
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external cohort of 941 samples, we demonstrated that, for 
the first time, a polygenic risk score was able to perform 
as well as the mid-parental height in predicting children’s 
adult height and in identifying children who would have 
adult short stature. Further, combining mid-parental height 
and the polygenic risk score provided better prediction ac-
curacy than either metric alone.
The polygenic risk score might provide clinical utility. 
For example, parental height may not be available due 
to various reasons (eg, many children do not know both 
parents’ height), and in many more cases it is inaccurately 
measured or reported, and thus a potentially erroneous esti-
mate might be supplied. Also, large discrepancies in parental 
heights render mid-parental height a less valid adult height 
predictor, particularly when some parents do not achieve 
their genetically determined height because of disease that 
is not inherited by the child. Under these circumstances, a 
polygenic risk score may be utilized instead, not only as 
a single predictor but also in other accurate multivariate 
predictive models, such as the Khamis-Roche method (13). 
Even though the self-reported height and weight measures 
during puberty in the ALSPAC cohort may contain meas-
urement errors, the superior performance of Khamis-Roche 
predictors over the mid-parental height or the polygenic 
risk score alone should encourage further investigations 
into incorporating an accurate genetic predictor into estab-
lished scoring schemes. We further demonstrated that even 
if only 1 parent could provide measured height, a combined 
predictor with the polygenic risk score could have import-
antly improved predictive and discriminative power over 
using the single parental height. We posit that these advan-
tages could be considered when undertaking genetic pre-
diction of adult height both in both clinical and research 
settings. Since genomewide genotyping has become more 
affordable (currently priced at approximately US$40 in 
a research context), is undertaken once in a lifetime, and 
could be used to predict several health outcomes, genetic 
prediction of adult height in children and adolescents could 
be widely and cost-effectively applied in research and clin-
ical practice.
Combining the polygenic risk score and the mid-
parental height could enhance predictive performance. 
Intuitively, the mid-parental height, while being a crude 
estimate of the genetic contribution, may additionally cap-
ture variance due to unmeasured environmental exposures 
shared by the parents and the children, particularly when 
families in a target population live in the same geographical 
area. This may partially explain the decrease of accuracy 
in mid-parental height prediction when a large discrep-
ancy exists in the parental height of a child. On the con-
trary, our polygenic risk score more accurately quantifies 
the genetic contribution toward height without measuring 
environmental exposures. Hence, the 2 predictors provide 
non-overlapping information. However, how proper cali-
bration should be carried out and whether a joint predictor 
is generalizable will require extensive exploration in future 
studies.
Our study has important limitations. First, our findings 
should be considered population-specific. Polygenic risk 
scores are usually not directly transferrable to a popula-
tion of a different ethnic background (36-39). Population-
specific polygenic risk scores should be developed to further 
explore their utility for height prediction, especially among 
non-European populations—once again underlining the 
importance of larger genetic studies of non-European an-
cestry that are currently scant. It should also be noted that 
the adult height of children in ALSPAC was, on average, 
3 to 4  cm taller than that in the UK Biobank, because 
the former represents a much younger population. We 
therefore adopted the definition of short stature as 2 SDs 
below population mean, instead of referring to a general 
population-based growth curve. Moreover, despite a high 
heritability, adult height is also influenced by a wide range 
of genetic and nongenetic factors not included in the poly-
genic risk score, including but not limited to chronic con-
ditions retarding growth (eg, genetic syndromes, such as 
Turner (40-42) and Prader-Willi syndromes (43-45), treat-
ment for childhood cancer (46, 47), acquired growth hor-
mone deficiency secondary to head trauma (35), etc.), rare 
pathogenic variants of large effects in pivotal genes (48-
50), and long-term medication (eg, use of inhaled cortico-
steroids (51-53)). Whether any interplay exists between the 
polygenic risk score and these risk factors may be tested 
with larger sample sizes and by testing the performance of 
this polygenic risk score in pediatric populations at risk for 
compromised growth.
Lastly, although not measured in our study cohorts, 
predictions based on current height and bone age re-
main powerful indicators of final adult height. In fact, in 
a few cases where bone age-based predictors were evalu-
ated, the proportion of variance explained by a combin-
ation of current height, chronological age, and bone age 
exceeded 60% at age 3 in both boys and girls (54) and 
continued increasing toward >99% by age 17, while the 
mid-parental height or the polygenic risk score alone could 
only account for approximately 40% of the total variance 
in sex-specific analyses. Nevertheless, it has been suggested 
that bone age-based predictors (eg, the Tanner-Whitehouse 
predictors) might also benefit from adding a genetic pre-
dictor, particularly for children with an extremely short or 
tall stature (54). Notably, a genetically predicted height is 
not sensitive to pubertal patterns (early or late puberty), 
which typically affect bone maturation, and this predictor 
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height predictions based on bone age are not precise before 
the age of 3 years. For all the previously discussed reasons 
and given the decreasing costs and increased accessibility 
of genomewide genotyping, we anticipate that a genetically 
predicted height may play a larger role in informing clinical 
decisions in the future.
Conclusions
In summary, we generated a polygenic risk score and dem-
onstrated that it could successfully predict adult height in 
a population of healthy children. Our findings support the 
use of this genetic predictor in certain settings as an alter-
native or in combination with traditional adult height pre-
dictors, such as mid-parental height, and possibly also with 
bone age-based methods to enhance screening for children 
at risk for short stature in adulthood.
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